Hormone Science, Reimagined
How a small change creates a big leap forward in women’s health
Our Innovation
Meet d3-Testosterone: A Molecular Reinvention
d3-T (AVA-291) is a novel, structurally identical form of testosterone where select hydrogen molecules have been substituted with deuterium. d3-T resists the conversion of testosterone (T) into estradiol (E2) — addressing one of the most significant barriers in T replacement therapy for women; the conversion of T to E2 in adipose tissue is linked to the development of or recurrence of breast cancer in postmenopausal women.
It’s testosterone, re-engineered for safety without sacrificing efficacy.
How It Works
Similar Efficacy. Smarter Science. Potentially Safer Outcomes.
d3-T has been designed to block the conversion of d3-T into E2, while leaving the remaining metabolic pathways of T unaffected.
Testosterone naturally converts into estradiol in the body through the aromatase enzyme. Aromatase is expressed locally in adipose tissue. The role of the conversion of T to E2 and its association with breast cancer is not completely understood, but a primary treatment for estrogen receptor+ breast cancer is a drug class called aromatase inhibitors and prior programs to develop T for use in postmenopausal women showed a signal for increased risk in breast cancer rates.
The Power of d3-T
- Highly resistant to the conversion to E2 by aromatase
- Similar androgen receptor affinity as T
- Excluding E2, similar metabolic profile as T
- Demonstrated direct substitution for T in a human clinical study
Early Results & Research
Promising Data, Clear Direction
d3-T is a novel, non-aromatizing androgen that mimics testosterone’s function without stimulating estrogen-sensitive breast cancer cells
- Proven androgen receptor engagement in vitro
- Early in vitro studies showed a lack of exacerbation of breast cancer cell proliferation
- Patent-protected through 2041
d3-T is on a fast track to becoming a foundational therapy in women’s health.
